Burgdorf - In business year 2006/07 the Ypsomed Group posted consolidated sales of CHF 277.5 million (-10.7% prior year), returning to profitability as announced in the second half of the year with consolidated net profits of CHF 2.7 million. Ypsomed is systematically executing on its strategy under a realigned management and organizational structure with a sharper focus on customers, optimized production and quality management, additional development and quality management staff and an expanded product range based on the in-house developed technology platforms including a new continuous injection device. Ypsomed also increased its level of investment last year from CHF 30.8 million for the year prior up to CHF 36.8 million for purposes including additional production space and expanding pen needle production in Solothurn. With over 219 patents, Ypsomed intends to consolidate on its position as the leading independent provider of injection systems for the self-administration of liquid medications. For business year 2007/08 Ypsomed projects revenues of around CHF 280 million (excluding acquisitions), with EBIT margin expanding to 10%. Ypsomed will be listing its shares on the BX Berne eXchange in addition to the SWX.
Press Releases Ypsomed Group